|
Search
Collections
Benchmarks
Upload document
Organization
Syndax Pharmaceuticals Inc.
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 abstract
Abstract
Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC).
Org:
Syndax Pharmaceuticals Inc.,
